Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609

Reuters

Sep 08

<a href="https://laohu8.com/S/SMHGF">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609

Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate $(ADC)$, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2565689544"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2565689544\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2565689544?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-08 20:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2565689544","market":"fut","top_or_hot":-1,"title":"Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSimcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-08 20:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SMHGF\">Simcere Pharmaceutical</a> Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250908:nNDL1KrB58:1","article_id":"2565689544","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2565689544","pubTimestamp":1757333501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate , developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1583":"高瓴概念","BK1191":"制药"},"translate_title":"先声药业集团宣布抗肿瘤创新药SIM0609获批临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":0.9},"content_text":"Simcere Pharmaceutical Group Announces Clinical Trial Approval for Innovative Anti-Tumor Drug SIM0609\n    \n\n        Simcere Pharmaceutical Group Ltd. has announced the approval of a clinical trial for its anti-tumor drug candidate, SIM0609, by the National Medical Products Administration of China. SIM0609 is a CDH17 Antibody-Drug Conjugate $(ADC)$, developed by Simcere, designed to target advanced solid tumors. The drug consists of a humanized monoclonal antibody linked to the company's proprietary topoisomerase I inhibitor through a novel hydrophilic cleavable linker. CDH17, highly expressed in various cancers such as gastric, colorectal, and pancreatic cancers, is identified as a promising therapeutic target for the treatment of advanced solid tumors, particularly gastrointestinal carcinomas. The results of the clinical trial have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simcere Pharmaceutical Group Ltd. published the original content used to generate this news brief on September 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}